RxSight, Inc. Announces Closing of Initial Public Offering

IPO, News, RxSight

RxSight, Inc., an ophthalmic medical device company, today announced the closing of its initial public offering raising $132MM. RxSight, Inc. is a commercial-stage medical technology company dedicated to improving the vision of patients following cataract surgery. The RxSight Light Adjustable Lens system, comprised of the RxSight Light Adjustable Lens (LAL®), RxSight Light Delivery Device (LDD) and accessories, is the first and only commercially available intraocular lens (IOL) technology that enables doctors to customize and optimize visual acuity for patients after cataract surgery. The LAL now features ActivShield™ technology, a revolutionary UV protection layer built into the lens.

Orasis Appoints Industry Veteran, Paul Smith, as President and Chief Operating Officer to Lead the Next Phase of Growth

News, Orasis

Orasis Pharmaceuticals, an emerging ophthalmic pharmaceutical company focused on developing an innovative pharmaceutical solution for the treatment of presbyopia symptoms, today announced the initiation of NEAR-1 and NEAR-2 Phase 3 clinical studies in the U.S., evaluating its novel eye drop candidate designed to improve near vision for people with presbyopia.

Visionary Ventures Closes Fund II with $114MM in Committed Capital

News, Visionary

Aliso Viejo, California, March 23, 2021 – Visionary Ventures today announced the closing of Visionary Venture Fund II with $114MM in committed capital. The Fund, which was strongly supported by existing and new investors, continues the firm’s strategy of partnering with Ophthalmology and Optometry Key Opinion Leader (KOL) limited partners to invest in ophthalmic pharmaceuticals and medical devices. Fund II enjoys investment and input from over 80 KOL experts spanning the front and back of the eye.

Re-Vana Therapeutics Names New Members to the Executive Team

News, Re-Vana

Re-Vana Therapeutics announced the appointment of Michael Nash as Chief Commercial Officer and David Shima, PhD, as Vice President of Research and Development. The two executives will play critical leadership roles at Re-Vana as the company develops innovative sustained release therapies for a broad range of ophthalmic indications, including wet age-related macular degeneration (AMD), diabetic retinopathy (DR), and glaucoma.

OIS Investor Perspectives Panel with Jeffry Weinhuff, Visionary Managing Partner, along with KKR, NEA, OrbiMed, & HIG

News, Visionary

Ophthalmology Innovation Summit Year in Review – Investor Perspectives

Participants:
Arjun Arora, Director – KKR
Ali Behbahani, MD, General Partner – NEA
Anat Naschitz, Managing Director – OrbiMed
Bruce Robertson, Managing Director – H.I.G. Capital
Jeffry Weinhuff, Managing Partner – Visionary Venture Fund

Moderated By:
William J. Link, PhD, Managing Partner – Flying L Partners

Orasis Closes $30MM Series C Round for Phase III Trials and Pre-Commercialization Activities.

News, Orasis

Orasis Pharmaceuticals, an emerging ophthalmic pharmaceutical company focused on developing an innovative pharmaceutical solution for the treatment of presbyopia symptoms, today announced the initiation of NEAR-1 and NEAR-2 Phase 3 clinical studies in the U.S., evaluating its novel eye drop candidate designed to improve near vision for people with presbyopia.

Tarsus Pharmaceuticals, Inc. Announces Closing of Initial Public Offering and Full Exercise by the Underwriters of Option to Purchase Additional Shares

IPO, News, Tarsus

Tarsus Pharmaceuticals, Inc. (“Tarsus”), a late clinical-stage biopharmaceutical company focused on the development and commercialization of therapeutic candidates to address large market opportunities initially in ophthalmic conditions, today announced the closing of its initial public offering of 6,325,000 shares of its common stock at a price to the public of $16.00 per share, which includes 825,000 shares sold upon full exercise of the underwriters’ option to purchase additional shares of common stock. All of the shares were offered by Tarsus. The aggregate gross proceeds to Tarsus from the offering, before deducting underwriting discounts and commissions and other offering expenses, were approximately $101.2 million.